Interview with Founder & Chief Scientific Officer of OX2 Therapeutics, Dr. Michael Olin

OX2 Therapeutics is a clinical-stage biopharmaceutical company developing new therapies to turn cancers into manageable and potentially curable diseases. In 2020 the company received clearance from the U.S. Food and Drug Administration to launch a Phase 1 clinical trial with its new combination therapy for treatment of recurrent high grade brain tumors for which no curative therapy is available. OX2 Therapeutics developed the first of its kind peptide platform that targets the activation receptor of the CD200 immune checkpoint. The peptide activates the immune system through a mechanism that modulates the suppressive effects of the CD200, PD-1/PD-L1 and CTLA4 immune checkpoints to allow a more robust anti-tumor response.